Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Biosense Webster, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This non-randomized study will examine the safety and efficacy of irrigated bipolar radiofrequency (RF) ablation in the treatment of ventricular tachycardia (VT) in patients for whom standard VT unipolar RF ablation has been unsuccessful. VT is a serious abnormality of the heart's electrical system. Ablation is a procedure that cauterizes heart tissue using catheters (long tubes that can be moved within or along the outside of the heart). Cauterizing the heart tissue is accomplished by using heat to damage the abnormal heart tissue that is not working well so that it can stop affecting the rest of the heart. Usually, heat is delivered using a unipolar catheter, in which energy travels from the catheter tip to a grounding pad. This research study seeks to find out if a bipolar ablation catheter, in which the energy travels between two catheter tips on either side of the heart muscle, can be used to eliminate the arrhythmia when the unipolar ablation is unsuccessful. The hypothesis is that the increased current density and improved rates of transmural lesion creation seen with bipolar RF ablation will lead to successful arrhythmia termination with minimal or no increased risk of complication.
STUDY OBJECTIVE This study will examine the role of irrigated bipolar radiofrequency (RF) ablation for the treatment of intramural ventricular tachycardia in patients who have failed standard unipolar RF ablation. The hypothesis is that the increased current density and improved rates of transmural lesion creation seen with bipolar RF ablation will lead to successful arrhythmia termination with minimal or no increased risk of complication.
INTRODUCTION, RATIONALE Radiofrequency (RF) ablation is the most commonly employed method for the catheter treatment of cardiac arrhythmias. Myocardial scar serves as the most frequent substrate for the genesis of both atrial and ventricular arrhythmia. Such scar frequently contains surviving myocyte bundles interspersed with fibrotic tissue, which leads to slow conduction. Areas of denser fibrosis cause conduction block. When appropriately arranged, conduction through or around these scars leads to the creation of a "reentry" circuit through which an arrhythmia is generated and maintained. Each reentry circuit contains within it an area called the isthmus, a portion of the circuit located in a position intimately related to the scar border zone. Electrical activation travels slowly through the isthmus before breaking out into normal myocardium. Ablation at the site of an isthmus will terminate a reentrant tachycardia.
A variety of techniques, including electroanatomic mapping and activation, entrainment, and substrate mapping, are employed during electrophysiologic (EP) study to identify areas of myocardial scar and potential isthmus sites. Points or lines of ablation using RF energy are then created in an attempt to interrupt the reentry circuit. Typically, unipolar RF energy is applied via a catheter tip electrode to the endocardial or epicardial surface of the heart and grounded via an electrode pad placed on the patient's skin. RF energy in this setting is dispersed through the entirety of the tissue between catheter tip and grounding pad. The standard 7-French, 4-mm tip catheters are highly successful at ablating circuits located within a few millimeters of the catheter tip. A focal, 1mm area of resistive heating occurs within the myocardium immediately in contact with the catheter tip; myocardial cell death occurs several millimeters more deeply through passive, conductive heating, which spreads outward from the contact point.
While the standard catheter is effective at the ablation of superficial arrhythmias, it has proven more problematic when used for deep myocardial sites or for creating transmural lesions. A number of alternatives have been developed in an attempt to access these sites. 8-mm or 10-mm catheter tips are able to create larger zones of resistive heating, delivering direct RF energy to a larger area of myocardium. A larger interface between catheter tip and blood improves cooling and allows for the delivery of more power without a rise in impedence. The clinical use of these larger catheters can, however, be limited by rapid temperature rises at the catheter-tissue interface, resulting in thrombus formation, char, and "steam pop" rupture of the endocardial surface. The use of irrigated ablation catheters have improved upon the ability to deliver RF energy without a sustained rise in impedance. Both open irrigated- and closed-loop irrigated catheters circulate saline along the catheter tip-myocardial interface, allowing for continued delivery of RF current without thrombus formation at the endocardial surface. Intramyocardial temperature rises accordingly without a concomitant endocardial temperature surge, creating larger and deeper myocardial ablation zones. Catheters featuring a retractable needle tipped electrode with intramyocardial saline infusion have also shown promise as a means of accessing deep myocardial circuits in ventricular tachycardia ablation, but are not currently available in the US. Transcoronary ethanol ablation has also been employed with moderate success in patients with arrhythmias resistant to endocardial catheter ablation. This technology, however, grants only limited control over the size of the resulting infarct and is restricted by the need for perfusion of the scar zone by an accessible coronary artery.
Nevertheless, there remain occasions in which an arrhythmia cannot be eliminated by standard unipolar ablation technique. This is seen most frequently due to deep intramural ventricular tachycardia, sometimes encountered following myocardial infarction. Both standard and alternative ablation strategies are frequently either unavailable or inadequate for termination of these arrhythmias.
Recently, several centers have employed irrigated bipolar ablation (BA) to target arrhythmias not amenable to unipolar ablation. During BA, two catheters are connected to either pole of an RF generator, allowing either catheter to function as the "active" catheter and the other the "return" catheter. Rather than being dispersed between the catheter tip and a distant grounding pad, BA concentrates energy between two catheter tips positioned on opposing sides of a target scar. BA may thus improve lesion transmurality through synergistic, simultaneous heating and increased current density leading to concentrated thermal injury.
Initial experience in the use of BA technology in mammalian hearts demonstrated that it could successfully be applied to create discrete areas of myocardial necrosis with minimal risk of complication. When compared to unipolar ablation, several studies suggested that BA could create larger areas of necrosis and transmural lesions with only rare episodes of perforation. Subsequent experience in human hearts was predominantly surgical: a large number of observational studies and reviews demonstrated the effectiveness and safety of BA in patients undergoing pulmonary vein isolation and Cox-Maze surgery as either isolated procedures or as adjuncts to valve replacement or coronary artery bypass surgery.
Despite its broad use during surgical ablation, the application of BA during catheter-based therapies is limited. Recently, our group demonstrated the utility of BA in both an in vitro model and in a series of patients with arrhythmia resistant to unipolar ablation. When compared to unipolar RF ablation, BA was found to be more likely to achieve transmural lesions in a porcine heart model (33% vs 82%, respectively, p = 0.001) and could do so in tissue up to 25 mm thickness. Clinically, all septal atrial flutters, 5 of 6 septal VTs, and 2 of 4 free-wall VTs were successfully acutely terminated.
The proposed study will further examine the role of BA in patients with ventricular tachycardia resistant to standard ablation techniques.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bipolar Ablation | Experimental | All patients who meet inclusion criteria and have VT not terminable with unipolar ablation will undergo bipolar ablation. |
|
| Registry | Active Comparator | Participants in Patient Registry after standard radiofrequency (VT) unipolar radiofrequency (RF) ablation was successful |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bipolar Ablation | Device | Patients will undergo bipolar ablation if unipolar ablation unsuccessful |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) | Freedom from recurrent VT at 6 months, defined as sustained ventricular tachycardia lasting longer than 30 seconds and identified due to clinical symptoms or during device interrogation. | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Procedural Complications | Total number of procedural complications which includes death, stroke, MI, heart failure, conduction abnormalities, pericardial effusion requiring drainage, hematoma, pseudoaneurysm | 6 months |
| Number of Participants With Post-ablation Inducibility of VT |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Srinivas Dukkipati, MD | Icahn School of Medicine at Mount Sinai | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Loyola University Medical Center | Maywood | Illinois | 60153 | United States | ||
| Brigham & Womans Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | All Patients | All patients who met inclusion criteria and have VT not terminable with unipolar ablation underwent bipolar ablation. |
| FG001 | Bipolar Ablation | Participants who underwent bipolar ablation after unipolar ablation unsuccessful |
| FG002 | Registry | Participants in Patient Registry after standard radiofrequency (VT) unipolar radiofrequency (RF) ablation was successful |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VT Induced Ablation |
|
| ||||||||||||||||||
| Arm Assignment |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Bipolar Ablation | Participants who underwent bipolar ablation after unipolar ablation unsuccessful |
| BG001 | Patient Registry | Participants in Patient Registry after standard radiofrequency (VT) unipolar radiofrequency (RF) ablation was successful |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) | Freedom from recurrent VT at 6 months, defined as sustained ventricular tachycardia lasting longer than 30 seconds and identified due to clinical symptoms or during device interrogation. | Posted | Count of Participants | Participants | 6 months |
|
6 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Bipolar Ablation | Bipolar Ablation: Patients underwent bipolar ablation when unipolar ablation unsuccessful |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cardiac Tamponade | Cardiac disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Complete Heart Block | Cardiac disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Srinivas R Dukkipati | Icahn School of Medicine at Mount Sinai | (212) 241-7114 | srinivas.dukkipati@mountsinai.org |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 24, 2016 | Jul 7, 2022 | Prot_SAP_000.pdf |
| ID | Term |
|---|---|
| D017180 | Tachycardia, Ventricular |
| D014693 | Ventricular Fibrillation |
| ID | Term |
|---|---|
| D013610 | Tachycardia |
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Number of participants to indicate incidence of the induction of any sustained arrhythmia post-ablation, with a duration > 15 seconds of monomorphic VT (MMVT). Post ablation inducibility is measured via program stimulation. |
| 6 months |
| Time to Arrhythmia Termination for the Bipolar Group Only | When bipolar ablation is performed during ongoing Ventricular Tachycardia (VT), the time to termination is the amount of ablation time that was necessary to cause VT to stop (terminate) | through termination, up to 60 seconds |
| Total Duration of Bipolar Ablation | Duration of bipolar ablation is the total procedure time | average of 345 minutes |
| Number of of Participants With Mortality | Number of participant from all cause mortality | 6 months |
| Boston |
| Massachusetts |
| 02115 |
| United States |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | United States |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | United States |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
| Texas Cardiac Arrhythmia Research Foundation | Austin | Texas | 78705 | United States |
| NOT COMPLETED |
|
|
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Secondary | Number of Procedural Complications | Total number of procedural complications which includes death, stroke, MI, heart failure, conduction abnormalities, pericardial effusion requiring drainage, hematoma, pseudoaneurysm | Posted | Number | events | 6 months |
|
|
|
| Secondary | Number of Participants With Post-ablation Inducibility of VT | Number of participants to indicate incidence of the induction of any sustained arrhythmia post-ablation, with a duration > 15 seconds of monomorphic VT (MMVT). Post ablation inducibility is measured via program stimulation. | Posted | Count of Participants | Participants | 6 months |
|
|
|
| Secondary | Time to Arrhythmia Termination for the Bipolar Group Only | When bipolar ablation is performed during ongoing Ventricular Tachycardia (VT), the time to termination is the amount of ablation time that was necessary to cause VT to stop (terminate) | Posted | Mean | Standard Deviation | seconds | through termination, up to 60 seconds |
|
|
|
| Secondary | Total Duration of Bipolar Ablation | Duration of bipolar ablation is the total procedure time | Posted | Mean | Standard Deviation | minutes | average of 345 minutes |
|
|
|
| Secondary | Number of of Participants With Mortality | Number of participant from all cause mortality | Posted | Count of Participants | Participants | 6 months |
|
|
|
| 9 |
| 49 |
| 26 |
| 49 |
| 14 |
| 49 |
| EG001 | Patient Registry | Participants in Patient Registry after standard radiofrequency (VT) unipolar radiofrequency (RF) ablation was successful | 5 | 60 | 25 | 60 | 8 | 60 |
| Recurrent Ventricular Tachycardia | Cardiac disorders | Systematic Assessment |
|
| Pulmonary Embolism Pneumonia | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Pericardial Effusion due to myocardial performation | Cardiac disorders | Systematic Assessment |
|
| Left Ventricular Thrombus | Cardiac disorders | Systematic Assessment |
|
| Pericardial Effusion | Cardiac disorders | Systematic Assessment |
|
| Hemorrhagic Shock | Cardiac disorders | Systematic Assessment |
|
| New Incessant Ventricular Tachycardia | Cardiac disorders | Systematic Assessment |
|
| Pericarditis | Cardiac disorders | Systematic Assessment |
|
| Hemothorax | Cardiac disorders | Systematic Assessment |
|
| Cardiac Arrest/anoxic brain injury | Cardiac disorders | Systematic Assessment |
|
| Implantable Cardioverter Defibrillator Shock | Cardiac disorders | Systematic Assessment |
|
| Chest pain/Fever | General disorders | Systematic Assessment |
|
| Pneumonia | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Lower Extremity Swelling/Weight Gain | General disorders | Systematic Assessment |
|
| Gastrointestinal Hemorrhage | Gastrointestinal disorders | Systematic Assessment |
|
| Hemodynamic decompensation/cardiac arrest post procedure | Cardiac disorders | Systematic Assessment |
|
| Total Artificial Heart Implantation/Severe atherosclerotic Coronary Artery Disease | Cardiac disorders | Systematic Assessment |
|
| Acute MI | Cardiac disorders | Systematic Assessment |
|
| Recurrent Ventricular Tachycardia/LVAD Implantation | Cardiac disorders | Systematic Assessment |
|
| Aortic Regurgitation requiring valve replacement | Cardiac disorders | Systematic Assessment |
|
| Generator change | Cardiac disorders | Systematic Assessment |
|
| Lead revision due to increased defibrillation threhold | Cardiac disorders | Systematic Assessment |
|
| Heart Transplant | Cardiac disorders | Systematic Assessment |
|
| Hemoperitoneum | Vascular disorders | Systematic Assessment |
|
| Cardiogenic Shock/Septic Shock | Cardiac disorders | Systematic Assessment |
|
| Gastrointestinal Bleed/Melena | Gastrointestinal disorders | Systematic Assessment |
|
| Pulseless Electrical Activity | Cardiac disorders | Systematic Assessment |
|
| Oopharyngeal swallow dysfunction | General disorders | Systematic Assessment |
|
| Hypercarbia and Fluid Overload | Cardiac disorders | Systematic Assessment |
|
| Congestive Heart Failure | Cardiac disorders | Systematic Assessment |
|
| Right Femoral Artery Pseudoaneurysm | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Fluid Overload | Cardiac disorders | Systematic Assessment |
|
| Right Ventricular Failure | Cardiac disorders | Systematic Assessment |
|
| Infection | Infections and infestations | Systematic Assessment |
|
| Hypoxic Brain Injury | Nervous system disorders | Systematic Assessment |
|
| recurrent ventricular tachycardia with biventricular failure | Cardiac disorders | Systematic Assessment |
|
| renal failure | Renal and urinary disorders | Systematic Assessment |
|
| new incessant ventricular tachycardia with redo ablation | Cardiac disorders | Systematic Assessment |
|
| back pain/diaphoresis/hematuria | General disorders | Systematic Assessment |
|
| pre-syncope and elevated cardiact enzymes | Cardiac disorders | Systematic Assessment |
|
| recurrent ventricular tachycardia/end stage heart failure | Cardiac disorders | Systematic Assessment |
|
| pneumoperitoneum, renal failure (intolerable to dialysis) | Renal and urinary disorders | Systematic Assessment |
|
| congestive heart failure/fluid overload | Cardiac disorders | Systematic Assessment |
|
| cerebrovascular accident/encephalopahty | Nervous system disorders | Systematic Assessment |
|
| orchitis | Infections and infestations | Systematic Assessment |
|
| food poisoining | General disorders | Systematic Assessment |
|
| cardiogenic shock | Cardiac disorders | Systematic Assessment |
|
| left femoral pseudoaneurysm | Injury, poisoning and procedural complications | Systematic Assessment |
|
| slurred speech | Nervous system disorders | Systematic Assessment |
|
| right subclavian/axillary thrombosis | Vascular disorders | Systematic Assessment |
|
| oropharynx bleeding | Injury, poisoning and procedural complications | Systematic Assessment |
|
| hypoxic respiratory failure | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| gastrointestinal bleed | Gastrointestinal disorders | Systematic Assessment |
|
| hemo-pneumothorax | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| lead modification | Cardiac disorders | Systematic Assessment |
|
| Acute Kidney Injury | Renal and urinary disorders | Systematic Assessment |
|
| Volume Overload | Cardiac disorders | Systematic Assessment |
|
| Groin Hematoma | Vascular disorders | Systematic Assessment |
|
| Urinary Tract Infection | Infections and infestations | Systematic Assessment |
|
| Post Ablation Hypotension | Vascular disorders | Systematic Assessment |
|
Not provided
| D000075224 |
| Cardiac Conduction System Disease |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |